CoChat

The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index, and 1 are not checked yet; none of the 62 sources its claims cite is checked for support yet.

Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters

Open access
Laloli, Kathryn J., Rentsch, Peggy, Stayte, Sandy, Vissel, Bryce · 2025 · Frontiers in Pharmacology

Abstract

Background: The cannabinoid receptor 2 (CB 2 ) is involved in regulating immune responses, yet its specific function in microglia remains poorly defined. This study aimed to generate and validate a microglia-specific, inducible CB 2 knockout mouse model incorporating reporter genes to enable precise detection of CB 2 expression and CB 2 knockout. Methods: A novel floxed CB 2 mouse line was generated, incorporating GFP and tdTomato reporter genes driven by the Cnr2 promoter to indicate CB 2 expression and CB 2 knockout, respectively. This line was crossed with Cx3cr1 or Tmem119 tamoxifen-inducible Cre lines to achieve macrophage- or microglia-specific CB 2 knockout, respectively. Behavioural testing, in vitro assays, sequencing and in vivo immunofluorescence were used to assess the efficiency and specificity of CB 2 knockout as well as potential off-target effects. Results: The floxed allele did not alter breeding or motor behaviour in mice, nor CB 2 function. CB 2 expression, indicated by GFP, followed expected patterns across tissues and conditions. Sequencing revealed both DNA and RNA of the floxed allele was as anticipated. Tamoxifen-induced Cre activity successfully initiated tdTomato expression exclusively in microglia of tamoxifen treated, Cre positive mice, validating the specificity and inducibility of CB 2 knockout. Microglial tdTomato expression confirmed successful CB 2 knockout in 9.3% of TmemCB 2 and 91.7% of Cx3CB 2 microglia. Peripheral tdTomato expression persisted beyond 3 weeks post-tamoxifen in Cx3CB 2 mice but was minimal in TmemCB 2 mice. Conclusion: This novel microglia-specific, inducible CB 2 knockout model is the first to combine a floxed CB 2 allele with reporter genes, an essential advancement given the lack of reliable CB 2 antibodies. The findings demonstrate the model’s specificity and effectiveness, while highlighting important considerations regarding Cre-mediated effects and recombination specificity. Furthermore, the floxed mouse can be crossed with any Cre line to study CB 2 expression and function in various tissues. This model provides a powerful platform for advancing understanding of CB 2 roles in microglia and supports future exploration of CB 2 -targeted therapeutic strategies.

Checked 2026-11-19 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

The authors generated and validated a novel floxed Cnr2 (CB2) mouse line in which GFP reports CB2 promoter activity and a Cre-dependent FLEx-switched tdTomato permanently marks cells that have undergone CB2 knockout. Crossed to Cx3cr1- or Tmem119-driven tamoxifen-inducible Cre lines, the model produced microglia-specific recombination without altering breeding, motor behaviour, or CB2 signalling, though peripheral recombination persisted beyond 3 weeks in the Cx3CB2 line.

Key findings

  • The floxed allele was functionally neutral: no differences from BL6 controls in litter size (F(3, 196) = 1.31, p = 0.27), mortality (KW(4, 200) = 3.79, p = 0.28), sex ratio (F(3, 192) = 0.094, p = 0.96), open-field distance (t(11) = 0.670, p = 0.516), or rotarod latency to fall (t(11) = 0.346, p = 0.736). Hu308-induced cAMP inhibition was equivalent across CB2flx, Cx3CB2, and BL6 in microglia (F(2,28) = 0.027, p = 0.973) and astrocytes (F(2,32) = 0.432, p = 0.653).
  • GFP expression matched expected CB2 distribution: minimal in naive CNS, strong in spleen white pulp, and markedly upregulated in the CNS after intrastriatal LPS.
  • Tamoxifen-induced tdTomato was microglia-specific and Cre-dependent, confirming CB2 knockout in 9.3% of TmemCB2 microglia (F(3, 8) = 18.23, p = 0.0006) and 91.7% of Cx3CB2 microglia; 94.3% of tdT signal colocalized with Iba1 in TmemCB2 mice, and >92% in Cx3CB2 mice, with no significant differences among the three tamoxifen protocols (F(2, 7) = 4.07, p = 0.067).
  • Peripheral tdT persisted in Cx3CB2 spleens beyond 3 weeks post-tamoxifen, contradicting the assumption that this washout yields microglia-restricted recombination; TmemCB2 spleens showed only rare tdT.

Methods

  • Generation of the C57BL/6-Cnr2 tm1(GFP,tdTomato)BViss/J (CB2flx) line: the entire Cnr2 coding region flanked by loxP sites, with GFP in sense orientation and a tdTomato cassette in inverse orientation flanked by lox2272 sites (FLEx switch), both under the Cnr2 promoter; crossed to Cx3cr1-Cre/ERT2 (Cx3CB2) and Tmem119-Cre/ERT2 (TmemCB2) lines.
  • Validation battery: DNA and mRNA sequencing (OzGene; Garvan Genetics Core), breeding outcome analysis (50 litters per strain), open-field and accelerating rotarod testing, primary glial cAMP assays with the CB2 agonist Hu308, and immunofluorescence colocalization (GFP, tdT, Iba1, CD68, GFAP, NeuN) quantified in FIJI with the Colocalization Object Counter plugin.
  • Tamoxifen regimens compared: 150 mg/kg every other day ×4, 100 mg/kg daily ×8, or 100 mg/kg twice daily ×10; tissue collected 3 weeks after the final injection. Neuroinflammation was induced by stereotaxic intrastriatal LPS (5 mg/mL, two 1 µL injections) with histology 15 days post-surgery. Statistics used Prism 10 with ANOVA and Tukey's, Dunnett's, Dunn's, or Šídák's post hoc tests.

Limitations

  • Stated: tdT is only expressed when the Cnr2 promoter is active, so because basal CNS CB2 expression is very low, most knockout cells would not be expected to express tdT — the authors note DNA-based methods such as in situ hybridisation are needed for definitive KO efficiency confirmation.
  • Stated: in Cx3CB2 Cre/+ microglia, overlapping GFP and YFP emission spectra could not be distinguished, preventing direct assessment of CB2-driven GFP in those cells; a 510 bp stretch of the 5′ homology arm yielded incomplete DNA sequencing data due to poor trace quality (though the low-quality region showed 100% identity to the predicted sequence).
  • Stated: tdT expression exceeded GFP expression in controls despite both being driven by the Cnr2 promoter, which the authors attribute speculatively to Cre toxicity — a hypothesis they explicitly say requires further research; they also note Tmem119 is downregulated in activated microglia and that 3 weeks is insufficient for peripheral clearance in the Cx3CB2 line, requiring a time-course study. Evident from the text: colocalization quantification used small group sizes (N = 3–4 per group).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2025.1682979

Cites

160 of 161 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Conditional CB2 knockout mechanism. The CB2flx mouse line contains genetic modifications in which the entire Cnr2 coding region (blue box) is surrounded by lox sites. The reporter genes GFP (sense orientation) and tdT (antisense orientation) are inserted into the Cnr2 locus under control of the Cnr2 promoter, such that cells expressing CB2 also express GFP. The CB2flx line is crossed with a Cre/ERT2 line to create an inducible CB2-knockout line. Following tamoxifen injection, Cre mediated recombination excises the floxed Cnr2 coding region and GFP, while flipping tdT into the sense orientation. Consequently, cells in which CB2 has been knocked out now express tdT as a marker of recombination. GFP, green fluorescent protein. tdT, tdTomato.
FIGURE 1 Conditional CB2 knockout mechanism. The CB2flx mouse line contains genetic modifications in which the entire Cnr2 coding region (blue box) is surrounded by lox sites. The reporter genes GFP (sense orientation) and tdT (antisense orientation) are inserted into the Cnr2 locus under control of the Cnr2 promoter, such that cells expressing CB2 also express GFP. The CB2flx line is crossed with a Cre/ERT2 line to create an inducible CB2-knockout line. Following tamoxifen injection, Cre mediated recombination excises the floxed Cnr2 coding region and GFP, while flipping tdT into the sense orientation. Consequently, cells in which CB2 has been knocked out now express tdT as a marker of recombination. GFP, green fluorescent protein. tdT, tdTomato.CC BY · PubMed Central
FIGURE 2 Litter characteristics are not impaired in genetically modified strains. (A) Number of pups born per litter. One-way ANOVA, Dunnett’s post hoc test. (B) Proportion of litter mortality between birth and weaning. One-way ANOVA, Dunnett’s post hoc test. (C) Proportion of pups that were female at weaning. One-way ANOVA, Dunn’s post hoc test. Data were collected from 50 litters per strain over a similar timeframe. Data are represented as mean ± SEM.
FIGURE 2 Litter characteristics are not impaired in genetically modified strains. (A) Number of pups born per litter. One-way ANOVA, Dunnett’s post hoc test. (B) Proportion of litter mortality between birth and weaning. One-way ANOVA, Dunnett’s post hoc test. (C) Proportion of pups that were female at weaning. One-way ANOVA, Dunn’s post hoc test. Data were collected from 50 litters per strain over a similar timeframe. Data are represented as mean ± SEM.CC BY · PubMed Central
FIGURE 3 Motor behaviour is not impaired in the CB2flx strain. (A–C) Open field and (D) rotarod motor behaviour tests in CB2flx mice. N = 6-7/group. Unpaired t-test. Data are represented as mean ± SEM.
FIGURE 3 Motor behaviour is not impaired in the CB2flx strain. (A–C) Open field and (D) rotarod motor behaviour tests in CB2flx mice. N = 6-7/group. Unpaired t-test. Data are represented as mean ± SEM.CC BY · PubMed Central
FIGURE 4 CB2 function is conserved in primary glia cultures. The CB2 agonist Hu308 inhibited cAMP production in primary (A) microglia and (B) astrocytes in a dose dependent manner in all strains. Data was normalised whereby 100% represents 0 mM Hu308 and 0% represents no forskolin control. N = 5-8/group. Two-way ANOVA, Dunnett’s post hoc test. Data are represented as mean ± SEM. Each point represents the mean of three technical replicates.
FIGURE 4 CB2 function is conserved in primary glia cultures. The CB2 agonist Hu308 inhibited cAMP production in primary (A) microglia and (B) astrocytes in a dose dependent manner in all strains. Data was normalised whereby 100% represents 0 mM Hu308 and 0% represents no forskolin control. N = 5-8/group. Two-way ANOVA, Dunnett’s post hoc test. Data are represented as mean ± SEM. Each point represents the mean of three technical replicates.CC BY · PubMed Central
FIGURE 5 Reporter gene expression reflects expected CB2 expression in CB2flx mice. Representative images of green fluorescent protein (GFP) and tdTomato (tdT) reporter gene expression in (A) the naive BL6 CNS, (B) naive CB2flx CNS, (C) naive CB2flx spleen, and (D) CB2flx CNS treated with intrastriatal LPS. Green arrows = GFP expression. Red arrows = tdT expression. Yellow arrows = GFP/tdT colocalization. Scale bar = 100 µm.
FIGURE 5 Reporter gene expression reflects expected CB2 expression in CB2flx mice. Representative images of green fluorescent protein (GFP) and tdTomato (tdT) reporter gene expression in (A) the naive BL6 CNS, (B) naive CB2flx CNS, (C) naive CB2flx spleen, and (D) CB2flx CNS treated with intrastriatal LPS. Green arrows = GFP expression. Red arrows = tdT expression. Yellow arrows = GFP/tdT colocalization. Scale bar = 100 µm.CC BY · PubMed Central
FIGURE 6 In Cx3CB2 mice, tdT expression is microglia specific and is Tam/Cre dependent. (A–D) Quantification of GFP and tdT colocalization with Iba1. Significance bars between Cx3CB2 Cre/+ groups only are shown. N = 3-4/group. An average of 133.4 (±4.3) Iba1+ cells were counted per n. Data are represented as mean ± SEM. One-way ANOVA with Tukey’s post hoc test, ****p ≤ 0.0001. Representative images of substantia nigra immunostaining in (E) BL6, (F) CB2flx, (G) Tam treated Cx3CB2 +/+, (H) Vehicle-treated Cx3CB2 Cre/+ and (I) Tam-treated Cx3CB2 Cre/+ animals. White arrows = GFP expression. Yellow arrows = GFP/tdT colocalization. Scale bar = 50 µm.
FIGURE 6 In Cx3CB2 mice, tdT expression is microglia specific and is Tam/Cre dependent. (A–D) Quantification of GFP and tdT colocalization with Iba1. Significance bars between Cx3CB2 Cre/+ groups only are shown. N = 3-4/group. An average of 133.4 (±4.3) Iba1+ cells were counted per n. Data are represented as mean ± SEM. One-way ANOVA with Tukey’s post hoc test, ****p ≤ 0.0001. Representative images of substantia nigra immunostaining in (E) BL6, (F) CB2flx, (G) Tam treated Cx3CB2 +/+, (H) Vehicle-treated Cx3CB2 Cre/+ and (I) Tam-treated Cx3CB2 Cre/+ animals. White arrows = GFP expression. Yellow arrows = GFP/tdT colocalization. Scale bar = 50 µm.CC BY · PubMed Central
FIGURE 7 In TmemCB2 mice, tdT expression is microglia specific and is Tam/Cre dependent. (A–D) Representative images of substantia nigra GFP/tdT/Iba1 immunostaining. (A) BL6, (B) Tam treated TmemCB2 +/+, (C) Vehicle treated TmemCB2 Cre/+ and (D) Tam treated TmemCB2 Cre/+. Scale bar = 50 µm. (E–G) Quantification of GFP and tdT with Iba1+ microglia. As only one group expressed tdT, G contains one panel only. N = 3/group. An average of 115.8 (±6.1) Iba1+ cells were counted per n. Data are represented as mean ± SEM. One-way ANOVA, Tukey’s post hoc test **p ≤ 0.01.
FIGURE 7 In TmemCB2 mice, tdT expression is microglia specific and is Tam/Cre dependent. (A–D) Representative images of substantia nigra GFP/tdT/Iba1 immunostaining. (A) BL6, (B) Tam treated TmemCB2 +/+, (C) Vehicle treated TmemCB2 Cre/+ and (D) Tam treated TmemCB2 Cre/+. Scale bar = 50 µm. (E–G) Quantification of GFP and tdT with Iba1+ microglia. As only one group expressed tdT, G contains one panel only. N = 3/group. An average of 115.8 (±6.1) Iba1+ cells were counted per n. Data are represented as mean ± SEM. One-way ANOVA, Tukey’s post hoc test **p ≤ 0.01.CC BY · PubMed Central
FIGURE 8 In TmemCB2 mice, reporter gene expression does not colocalize with astrocytes or neurons. Representative images of immunostaining in the substantia nigra. GFP and tdT with either (A–C) GFAP or (D–F) NeuN. (A,D) Tam treated TmemCB2 +/+, (B,E) Vehicle treated TmemCB2 Cre/+ (C,F) Tam treated TmemCB2 Cre/+. Scale bar = 20 µm.
FIGURE 8 In TmemCB2 mice, reporter gene expression does not colocalize with astrocytes or neurons. Representative images of immunostaining in the substantia nigra. GFP and tdT with either (A–C) GFAP or (D–F) NeuN. (A,D) Tam treated TmemCB2 +/+, (B,E) Vehicle treated TmemCB2 Cre/+ (C,F) Tam treated TmemCB2 Cre/+. Scale bar = 20 µm.CC BY · PubMed Central
FIGURE 9 Reporter gene expression is present in the TmemCB2 spleen. Representative immunofluorescent images of Tam treated (A,B) TmemCB2 +/+ and (C,D) TmemCB2 Cre/+ spleens. Red arrows = tdT expression. Scale bar = 100 µm.
FIGURE 9 Reporter gene expression is present in the TmemCB2 spleen. Representative immunofluorescent images of Tam treated (A,B) TmemCB2 +/+ and (C,D) TmemCB2 Cre/+ spleens. Red arrows = tdT expression. Scale bar = 100 µm.CC BY · PubMed Central
FIGURE 10 Immunofluorescence analysis of reporter gene expression in the striatum of LPS-lesioned TmemCB2 Cre/+ mice. Representative images from vehicle- and tamoxifen-treated mice are shown for both ipsilateral and contralateral striata. Red arrows = tdT expression. Green arrows = GFP expression. Yellow arrows = GFP and tdT coexpression. Solid arrows = reporter gene colocalizing with CD68. Hollow arrows = reporter gene not colocalizing with CD68. White arrows indicate CD68 expression only. Scale bar = 25uM.
FIGURE 10 Immunofluorescence analysis of reporter gene expression in the striatum of LPS-lesioned TmemCB2 Cre/+ mice. Representative images from vehicle- and tamoxifen-treated mice are shown for both ipsilateral and contralateral striata. Red arrows = tdT expression. Green arrows = GFP expression. Yellow arrows = GFP and tdT coexpression. Solid arrows = reporter gene colocalizing with CD68. Hollow arrows = reporter gene not colocalizing with CD68. White arrows indicate CD68 expression only. Scale bar = 25uM.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 3 Not valid · 31 Not checked · 134 Own results and interpretations

120 more claims

Create a free account to see all 168 claims and to verify the 51 references still open.

See all claims — free account
  • The quote only partly states this claim. 1
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • ConsistentF(3, 196) = 1.31reported p = .27 · recomputed p = .272

    “F (3, 196) = 1.31, p = .27”

  • ConsistentF(3, 192) = 0.094reported p = .96 · recomputed p = .963

    “F (3, 192) = 0.094, p = .96”

  • Consistentt(11) = 0.67reported p = .516 · recomputed p = .517

    “t (11) = 0.670, p = .516”

  • Consistentt(11) = 0.421reported p = .682 · recomputed p = .682

    “t (11) = 0.421, p = .682”

  • Consistentt(11) = 1.138reported p = .279 · recomputed p = .279

    “t (11) = 1.138, p = .279”

5 of 13 · the rest aren’t loaded

8 more recomputed tests

Create a free account to see every test the Stats check recomputed.

See all tests — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 161 references

Cited by

See all 3

Metadata

Authors
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B.
Affiliations
  • UNSW Sydney (AU)
  • St Vincent's Hospital Sydney (AU)
Corresponding author
Vissel, Bryce
Venue
Frontiers in Pharmacology
Published
2025-11-19
Volume
16
Pages
1682979-1682979
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4416403131
Cited by
3
References
159
Citations by year
2026: 3
FWCI
1.05
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Australian Government
  • University of New South Wales
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
Keywords
CB2 receptor, CNR2, floxed allele, microglia, tamoxifen-inducible Cre, CX3CR1, TMEM119, off-target effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.